IRX Therapeutics raises $31.6M to start Phase 2B trials of its ‘generic’ immunity-boosting cancer drug
New York biotech IRX Therapeutics just raised $31.6 million to finance later stage trials of its fast-tracked immunity-boosting cancer therapeutic, IRX-2. The randomized head and neck cancer Phase 2B trial will study about 200 patients, with clinical trial centers in the U.S. and Western Europe. The company’s therapy ups the immune response of cancer patients, helping their […]